Experts hail ‘new age of diabetes treatment’ as drug approved on NHS (opens original article in a new tab)

The NHS has approved teplizumab, a drug that delays type 1 diabetes onset for up to three years, marking a significant advancement in treatment. Key points include its 14-day intravenous administration, initial eligibility for 1,100 patients, and recognition as a breakthrough by health organizations. The drug trains the immune system to stop attacking pancreatic cells, offering patients valuable time before needing insulin management.

• NHS approves teplizumab to delay type 1 diabetes onset for up to three years
• Teplizumab is given as a 14-day intravenous treatment course for early-stage patients
• 1,100 people could be eligible in the first year, decreasing to 820 in subsequent years
• Diabetes UK and Nice highlight teplizumab as a breakthrough targeting diabetes' root cause